{"id":"https://openalex.org/W4311399197","doi":"https://doi.org/10.1111/dom.14946","title":"A phase 2a, randomized, double\u2010blind, placebo\u2010controlled, three\u2010arm, parallel\u2010group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF \u201006835919 in patients with non\u2010alcoholic fatty liver disease and type 2 diabetes","display_name":"A phase 2a, randomized, double\u2010blind, placebo\u2010controlled, three\u2010arm, parallel\u2010group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF \u201006835919 in patients with non\u2010alcoholic fatty liver disease and type 2 diabetes","alternate_titles":[],"publication_year":2023,"publication_date":"2023-01-17","ids":{"openalex":"https://openalex.org/W4311399197","doi":"https://doi.org/10.1111/dom.14946","pmid":"https://pubmed.ncbi.nlm.nih.gov/36515213"},"language":"en","primary_location":{"id":"doi:10.1111/dom.14946","doi":"https://doi.org/10.1111/dom.14946","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.14946","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14946","source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4311399197"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14946","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102756128","display_name":"Aditi R. Saxena","orcid":"https://orcid.org/0000-0001-6017-1838","observed_orcids":["https://orcid.org/0000-0001-6017-1838"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Aditi R. Saxena","raw_affiliation_strings":["Pfizer Worldwide Research and Development, Cambridge, Massachusetts, USA"],"raw_orcid":"https://orcid.org/0000-0001-6017-1838","affiliations":[{"raw_affiliation_string":"Pfizer Worldwide Research and Development, Cambridge, Massachusetts, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029900410","display_name":"Stephanie\u2010An Lyle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stephanie\u2010An Lyle","raw_affiliation_strings":["Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022620370","display_name":"Kaivan Khavandi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kaivan Khavandi","raw_affiliation_strings":["Pfizer Worldwide Research and Development, Cambridge, Massachusetts, USA","Affiliation at the time this study was conducted"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Worldwide Research and Development, Cambridge, Massachusetts, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Affiliation at the time this study was conducted","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037717373","display_name":"Ruolun Qiu","orcid":"https://orcid.org/0000-0002-4051-6680","observed_orcids":["https://orcid.org/0000-0002-4051-6680"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ruolun Qiu","raw_affiliation_strings":["Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110416431","display_name":"Mark Whitlock","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189718659","display_name":"Pfizer (United Kingdom)","ror":"https://ror.org/04x4v8p40","country_code":"GB","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I189718659"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mark Whitlock","raw_affiliation_strings":["Early Clinical Development, Pfizer Inc, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Early Clinical Development, Pfizer Inc, Cambridge, UK","institution_ids":["https://openalex.org/I189718659"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056866147","display_name":"William P. Esler","orcid":"https://orcid.org/0000-0003-4783-8620","observed_orcids":["https://orcid.org/0000-0003-4783-8620"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"William P. Esler","raw_affiliation_strings":["Pfizer Worldwide Research and Development, Cambridge, Massachusetts, USA"],"raw_orcid":"https://orcid.org/0000-0003-4783-8620","affiliations":[{"raw_affiliation_string":"Pfizer Worldwide Research and Development, Cambridge, Massachusetts, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5034392342","display_name":"Albert M. Kim","orcid":"https://orcid.org/0000-0002-5269-2155","observed_orcids":["https://orcid.org/0000-0002-5269-2155"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Albert M. Kim","raw_affiliation_strings":["Pfizer Worldwide Research and Development, Cambridge, Massachusetts, USA","Affiliation at the time this study was conducted"],"raw_orcid":"https://orcid.org/0000-0002-5269-2155","affiliations":[{"raw_affiliation_string":"Pfizer Worldwide Research and Development, Cambridge, Massachusetts, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Affiliation at the time this study was conducted","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5102756128"],"corresponding_institution_ids":["https://openalex.org/I180857899"],"apc_list":{"value":4940,"currency":"USD","value_usd":4940},"apc_paid":{"value":4940,"currency":"USD","value_usd":4940},"fwci":5.6833,"has_fulltext":true,"cited_by_count":51,"citation_normalized_percentile":{"value":0.97793998,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"25","issue":"4","first_page":"992","last_page":"1001"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10351","display_name":"Liver Disease Diagnosis and Treatment","score":0.9609000086784363,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10351","display_name":"Liver Disease Diagnosis and Treatment","score":0.9609000086784363,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.030700000002980232,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-alcoholic-fatty-liver-disease","display_name":"non-alcoholic fatty liver disease","score":0.9819999933242798},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.996999979019165},{"id":"https://openalex.org/keywords/hepatic-steatosis","display_name":"hepatic steatosis","score":0.8690000176429749},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.925000011920929},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.7910000085830688},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.7900000214576721},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.7400000095367432},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.8309999704360962},{"id":"https://openalex.org/keywords/proton-density-fat-fraction","display_name":"proton density fat fraction","score":0.6000000238418579}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9036307334899902},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8352134823799133},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.8201107978820801},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6774141788482666},{"id":"https://openalex.org/C2991744798","wikidata":"https://www.wikidata.org/wiki/Q608510","display_name":"Double blind","level":4,"score":0.4643704295158386},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.43654438853263855},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.41948771476745605},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.2802324593067169},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.18866708874702454},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.06602689623832703},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065626","descriptor_name":"Non-alcoholic Fatty Liver Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/dom.14946","doi":"https://doi.org/10.1111/dom.14946","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.14946","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14946","source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:36515213","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36515213","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Randomized Controlled Trial"}],"best_oa_location":{"id":"doi:10.1111/dom.14946","doi":"https://doi.org/10.1111/dom.14946","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.14946","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14946","source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G1588314721","display_name":null,"funder_award_id":"GPP 2022","funder_id":"https://openalex.org/F4320307765","funder_display_name":"Pfizer"}],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4311399197.pdf","grobid_xml":"https://content.openalex.org/works/W4311399197.grobid-xml"},"referenced_works_count":33,"referenced_works":["https://openalex.org/W6798375","https://openalex.org/W1974062643","https://openalex.org/W2049140858","https://openalex.org/W2064530619","https://openalex.org/W2103583101","https://openalex.org/W2105476490","https://openalex.org/W2128157888","https://openalex.org/W2136909828","https://openalex.org/W2139351004","https://openalex.org/W2146966453","https://openalex.org/W2161102718","https://openalex.org/W2164092292","https://openalex.org/W2470838351","https://openalex.org/W2593684862","https://openalex.org/W2734724639","https://openalex.org/W2740802165","https://openalex.org/W2751789497","https://openalex.org/W2761848926","https://openalex.org/W2785515118","https://openalex.org/W2788821298","https://openalex.org/W2789920657","https://openalex.org/W2790101519","https://openalex.org/W2982095812","https://openalex.org/W2998761381","https://openalex.org/W3110042762","https://openalex.org/W3111389110","https://openalex.org/W3134871436","https://openalex.org/W3159149675","https://openalex.org/W3182981822","https://openalex.org/W3205941711","https://openalex.org/W3212624973","https://openalex.org/W4293733558","https://openalex.org/W4296581360"],"related_works":["https://openalex.org/W3159149675","https://openalex.org/W2937946373","https://openalex.org/W3205941711","https://openalex.org/W3129584656","https://openalex.org/W7171529410","https://openalex.org/W3188271807","https://openalex.org/W2113064802","https://openalex.org/W4379058092","https://openalex.org/W3092443860","https://openalex.org/W2997878947"],"abstract_inverted_index":{"AIM:":[0],"To":[1],"assess":[2],"the":[3,10,118,161,206],"safety,":[4],"tolerability":[5],"and":[6,22,52,96,107,114,156,165,203,210,228,231,241],"pharmacodynamics":[7],"(PD)":[8],"of":[9,57],"ketohexokinase":[11],"inhibitor":[12],"PF-06835919":[13,66,124,130,163,208,220],"in":[14,90,98,147,160,180,184,205,233,235,237],"participants":[15,112,238],"with":[16,37,214,239],"non-alcoholic":[17],"fatty":[18],"liver":[19,42],"disease":[20],"(NAFLD)":[21],"type":[23],"2":[24],"diabetes":[25],"(T2D).":[26],"MATERIALS":[27],"AND":[28],"METHODS:":[29],"This":[30],"double-blind,":[31],"placebo-controlled,":[32],"parallel-group":[33],"study":[34],"enrolled":[35],"adults":[36],"NAFLD":[38,240],"(\u2265":[39,59],"8%":[40],"whole":[41],"fat":[43,49],"[WLF]":[44],"using":[45,92],"MRI":[46],"proton":[47],"density":[48],"fraction":[50],"[MRI-PDFF])":[51],"T2D":[53],"on":[54],"stable":[55],"doses":[56],"metformin":[58],"500":[60],"mg/day).":[61],"Participants":[62],"received":[63],"once-daily":[64],"placebo,":[65,162,173,207],"150":[67,125],"or":[68],"300":[69,131],"mg":[70],"for":[71],"16":[72,103,223],"weeks.":[73],"Randomization":[74],"(1:1:1)":[75],"was":[76,149,197,225],"via":[77],"an":[78],"interactive":[79],"response":[80],"technology":[81],"system.":[82],"Endpoints":[83],"included":[84],"percentage":[85,145],"change":[86],"from":[87],"baseline":[88],"(CFB)":[89],"WLF":[91,148,236],"MRI-PDFF":[93],"(primary":[94],"endpoint)":[95,101],"CFB":[97,146],"HbA1c":[99,181],"(co-primary":[100],"at":[102],"weeks,":[104],"PD,":[105],"safety":[106],"tolerability.":[108],"RESULTS:":[109],"Among":[110],"164":[111],"randomized":[113],"treated,":[115],"145":[116],"completed":[117],"treatment":[119],"(placebo,":[120],"n":[121,127,133],"=":[122,128,134,175],"50;":[123],"mg,":[126,132],"46;":[129],"49).":[135],"At":[136],"week":[137],"16,":[138],"least":[139],"squares":[140],"mean":[141],"(90%":[142],"confidence":[143],"interval)":[144],"-5.26%":[150],"(-12.86%,":[151],"2.99%),":[152],"-17.05%":[153],"(-24.01%,":[154],"-9.46%)":[155],"-19.13%":[157],"(-25.51%,":[158],"-12.20%)":[159],"150-mg":[164,209],"300-mg":[166,170,211],"groups,":[167,212],"respectively":[168],"(PF-06835919":[169],"group":[171],"vs.":[172],"P":[174],".0288).":[176],"Modest":[177],"numerical":[178],"reductions":[179,234],"were":[182],"observed":[183],"all":[185],"groups":[186,200],"that":[187],"did":[188],"not":[189],"reach":[190],"statistical":[191],"significance.":[192],"Treatment-emergent":[193],"adverse":[194],"event":[195],"incidence":[196],"similar":[198],"across":[199],"(40.7%,":[201],"45.5%":[202],"32.7%":[204],"respectively),":[213],"no":[215],"apparent":[216],"dose-related":[217],"trend.":[218],"CONCLUSIONS:":[219],"administration":[221],"over":[222],"weeks":[224],"generally":[226],"safe":[227],"well":[229],"tolerated":[230],"resulted":[232],"T2D.":[242]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4311399197","counts_by_year":[{"year":2026,"cited_by_count":17},{"year":2025,"cited_by_count":20},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":6}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2022-12-26T00:00:00"}
